Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.

Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators.

Clin Cancer Res. 2020 Feb 7. doi: 10.1158/1078-0432.CCR-18-1140. [Epub ahead of print]

PMID:
32034072
2.

Leptomeningeal metastasis from solid tumors.

Thakkar JP, Kumthekar P, Dixit KS, Stupp R, Lukas RV.

J Neurol Sci. 2020 Jan 23;411:116706. doi: 10.1016/j.jns.2020.116706. [Epub ahead of print] Review.

PMID:
32007755
3.

Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?

Arrieta VA, Iwamoto F, Lukas RV, Sachdev S, Rabadan R, Sonabend AM.

J Neurosurg. 2019 Dec 6:1-6. doi: 10.3171/2019.9.JNS192523. [Epub ahead of print] No abstract available.

PMID:
31812138
4.

A Report from the 2017 Sino-US Medical Education Symposium in Wuhan, China.

Lukas RV, Jiang I, Lio J, Cooper B, Dong H, Fan J, Sherer R.

Educ Health (Abingdon). 2019 May-Aug;32(2):99-100. doi: 10.4103/efh.EfH_206_17. No abstract available.

5.

Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.

Drumm MR, Dixit KS, Grimm S, Kumthekar P, Lukas RV, Raizer JJ, Stupp R, Chheda MG, Kam KL, McCord M, Sachdev S, Kruser T, Steffens A, Javier R, McCortney K, Horbinski C.

Neuro Oncol. 2019 Nov 10. pii: noz216. doi: 10.1093/neuonc/noz216. [Epub ahead of print]

PMID:
31711239
6.

Immunotherapy Against Gliomas: is the Breakthrough Near?

Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM.

Drugs. 2019 Nov;79(17):1839-1848. doi: 10.1007/s40265-019-01203-z. Review.

PMID:
31598900
7.

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.

Kosche C, Stout M, Sosman J, Lukas RV, Choi JN.

Melanoma Res. 2019 Sep 24. doi: 10.1097/CMR.0000000000000642. [Epub ahead of print]

PMID:
31567590
8.

Pleomorphic xanthoastrocytoma: a brief review.

Shaikh N, Brahmbhatt N, Kruser TJ, Kam KL, Appin CL, Wadhwani N, Chandler J, Kumthekar P, Lukas RV.

CNS Oncol. 2019 Nov 1;8(3):CNS39. doi: 10.2217/cns-2019-0009. Epub 2019 Sep 19.

9.

Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.

Chiocca EA, Yu JS, Lukas RV, Solomon IH, Ligon KL, Nakashima H, Triggs DA, Reardon DA, Wen P, Stopa BM, Naik A, Rudnick J, Hu JL, Kumthekar P, Yamini B, Buck JY, Demars N, Barrett JA, Gelb AB, Zhou J, Lebel F, Cooper LJN.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaaw5680. doi: 10.1126/scitranslmed.aaw5680.

PMID:
31413142
10.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Dec 17;21(12):1498-1508. doi: 10.1093/neuonc/noz119.

PMID:
31276167
11.

The interplay among psychological distress, the immune system, and brain tumor patient outcomes.

Otto-Meyer S, Lumibao J, Kim E, Ladomersky E, Zhai L, Lauing KL, Scholtens DM, Penedo F, Amidei C, Lukas RV, Wainwright DA.

Curr Opin Behav Sci. 2019 Aug;28:44-50. doi: 10.1016/j.cobeha.2019.01.009. Epub 2019 Feb 26.

PMID:
31049368
12.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
13.

The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.

Ladomersky E, Scholtens DM, Kocherginsky M, Hibler EA, Bartom ET, Otto-Meyer S, Zhai L, Lauing KL, Choi J, Sosman JA, Wu JD, Zhang B, Lukas RV, Wainwright DA.

Front Pharmacol. 2019 Mar 27;10:200. doi: 10.3389/fphar.2019.00200. eCollection 2019.

14.

Newly Diagnosed Glioblastoma: A Review on Clinical Management.

Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R.

Oncology (Williston Park). 2019 Mar 13;33(3):91-100. Review.

15.

Improving survival in molecularly selected glioblastoma.

Stupp R, Lukas RV, Hegi ME.

Lancet. 2019 Feb 16;393(10172):615-617. doi: 10.1016/S0140-6736(18)33211-2. Epub 2019 Feb 14. No abstract available.

PMID:
30782332
16.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

17.

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017).

Zhai L, Ladomersky E, Lauing KL, Wu M, Scholtens DM, Savoor R, Zhang B, Wu JD, Horbinski C, Lukas RV, Binder DC, Wainwright DA.

Oncoimmunology. 2018 Dec 13;8(3):1548242. doi: 10.1080/2162402X.2018.1548242. eCollection 2019.

18.

"Neuro-oncology research in Nigeria: a great untapped potential".

Adekanmbi A, Peters KB, Razis E, Adeolu AA, Lukas RV, Balogun JA.

World Neurosurg. 2019 Jan 16. pii: S1878-8750(19)30066-X. doi: 10.1016/j.wneu.2018.12.192. [Epub ahead of print]

PMID:
30659966
19.

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L.

Lung Cancer. 2019 Feb;128:105-112. doi: 10.1016/j.lungcan.2018.12.017. Epub 2018 Dec 19.

PMID:
30642441
20.

Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.

Lukas RV, Juhász C, Wainwright DA, James CD, Kennedy E, Stupp R, Lesniak MS.

J Neurooncol. 2019 Jan;141(1):111-120. doi: 10.1007/s11060-018-03013-x. Epub 2018 Nov 10.

21.

Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma.

Binder DC, Ladomersky E, Lenzen A, Zhai L, Lauing KL, Otto-Meyer SD, Lukas RV, Wainwright DA.

Transl Cancer Res. 2018 Apr;7(Suppl 4):S510-S513. No abstract available.

22.

Reader response: Education Research: Difficult conversations in neurology: Lessons learned from medical students.

Lukas RV.

Neurology. 2018 Sep 25;91(13):635-636. doi: 10.1212/WNL.0000000000006236. No abstract available.

PMID:
30249676
23.

Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.

Hussain F, Horbinski CM, Chmura SJ, Yamini B, Lukas RV.

Neurologist. 2018 Sep;23(5):163-166. doi: 10.1097/NRL.0000000000000194.

PMID:
30169370
24.

An overview of meningiomas.

Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV.

Future Oncol. 2018 Sep;14(21):2161-2177. doi: 10.2217/fon-2018-0006. Epub 2018 Aug 7. Review.

25.

Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O'Hear C, Grossman W, Baehring J.

J Neurooncol. 2018 Nov;140(2):317-328. doi: 10.1007/s11060-018-2955-9. Epub 2018 Aug 2.

PMID:
30073642
26.
27.

BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.

Lukas RV, Merrell RT.

CNS Oncol. 2018 Apr;7(2):CNS10. doi: 10.2217/cns-2017-0032. Epub 2018 Apr 30.

28.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C.

Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051.

29.

Neurosciences Continuing Education: An Adult With New-Onset Seizures.

Lukas RV.

J Neurosci Nurs. 2018 Apr;50(2):100-101. doi: 10.1097/JNN.0000000000000351.

PMID:
29521733
30.

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, Gritsina G, Sun X, Liu Y, Yu F, Gong W, Liu Y, Jiang B, Tang T, Patel R, Platanias LC, James CD, Stupp R, Lukas RV, Binder DC, Wainwright DA.

Clin Cancer Res. 2018 Jun 1;24(11):2559-2573. doi: 10.1158/1078-0432.CCR-17-3573. Epub 2018 Mar 2.

31.

Diagnostic Evaluation in Primary CNS Lymphoma.

Lukas RV, Riedell P, Horowitz PM, Pytel P, Kamson DO.

Neurologist. 2018 Mar;23(2):53-54. doi: 10.1097/NRL.0000000000000169.

PMID:
29494436
32.

Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions.

Lukas RV, Gondi V, Stupp R, Raizer JJ.

Oncology (Williston Park). 2018 Feb 15;32(2):e11-e19. Review.

33.

Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis.

Lukas RV, Stupp R, Gondi V, Raizer JJ.

Oncology (Williston Park). 2018 Jan 15;32(1):17-22. Review.

34.

Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy.

Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, Tao JX, Warnke P, Rose S, Towle VL, Wu S.

Epilepsy Behav. 2018 Mar;80:331-336. doi: 10.1016/j.yebeh.2018.01.021. Epub 2018 Feb 9. Review.

PMID:
29433947
35.

Case Report of Bone Marrow-Sparing Proton Therapy Craniospinal Irradiation for Central Nervous System Myelomatosis.

Kauffmann G, Buerki RA, Lukas RV, Gondi V, Chmura SJ.

Cureus. 2017 Nov 28;9(11):e1885. doi: 10.7759/cureus.1885.

36.

Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma.

Grahnke KA, Heiferman DM, Borys E, Melian E, Barton KP, Lukas RV, Shaikh N, Leonetti JP, Anderson DE.

Brain Tumor Pathol. 2018 Apr;35(2):123-126. doi: 10.1007/s10014-017-0306-8. Epub 2018 Jan 13. No abstract available.

PMID:
29330645
37.

Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.

Lukas RV, Mrugala MM.

Neurooncol Pract. 2017 Dec;4(4):209-219. doi: 10.1093/nop/npw016. Epub 2016 Aug 26. Review.

38.

A Survey of the Neuro-Oncology Landscape.

Lukas RV, Wu J, Dey M, Buerki RA, Byrne RW, Dohrmann GJ.

J Clin Neurol. 2018 Jan;14(1):8-15. doi: 10.3988/jcn.2018.14.1.8. Epub 2017 Oct 31. Review.

39.

Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas.

Fetcko K, Lukas RV, Watson GA, Zhang L, Dey M.

Medicine (Baltimore). 2017 Oct;96(43):e8293. doi: 10.1097/MD.0000000000008293. Review.

40.

State-of-the-art considerations in small cell lung cancer brain metastases.

Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R.

Oncotarget. 2017 Jul 18;8(41):71223-71233. doi: 10.18632/oncotarget.19333. eCollection 2017 Sep 19. Review.

41.

Hospital volume and group expertise in newly diagnosed glioblastoma management.

Lukas RV, Lesniak MS, Stupp R.

J Neurooncol. 2018 Jan;136(1):213-214. doi: 10.1007/s11060-017-2632-4. Epub 2017 Oct 7. No abstract available.

PMID:
28988378
42.

Management of glioblastoma in elderly patients.

Young JS, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas RV.

J Neurol Sci. 2017 Sep 15;380:250-255. doi: 10.1016/j.jns.2017.07.048. Epub 2017 Aug 1. Review.

PMID:
28870580
43.

Skin toxicities associated with tumor treating fields: case based review.

Lukas RV, Ratermann KL, Wong ET, Villano JL.

J Neurooncol. 2017 Dec;135(3):593-599. doi: 10.1007/s11060-017-2612-8. Epub 2017 Aug 28.

PMID:
28849343
44.

Tumor Treating Fields in Neuro-Oncological Practice.

Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV.

Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8. Review.

PMID:
28664468
45.

Added diagnostic utility of PET in a patient with subacute encephalopathy and small-cell lung cancer.

Gera A, Kamson DO, Villaflor VM, Lukas RV.

Lung Cancer Manag. 2017 Jul;6(1):9-16. doi: 10.2217/lmt-2016-0020. Epub 2017 Jul 14.

46.

CNS hemangioblastomatosis in a patient without von Hippel-Lindau disease.

Franco A, Pytel P, Lukas RV, Chennamaneni R, Collins JM.

CNS Oncol. 2017 Apr;6(2):101-105. doi: 10.2217/cns-2016-0027.

47.

Pausing to reflect in a high-volume clinical milieu.

Lukas RV, Albert DV.

Perspect Med Educ. 2017 Feb;6(1):61-62. doi: 10.1007/s40037-016-0316-y. No abstract available.

48.

Views on Careers in Clinical Neurosciences Among Neurosurgeons and Neurologists in China.

Lukas RV, Ma C, Chen J, Dong H, Li J, Wang Z, Jiang I, Fu K, Satnarayan S, Albert DV, Sherer R.

World Neurosurg. 2017 Feb;98:532-537. doi: 10.1016/j.wneu.2016.11.054. Epub 2016 Nov 19.

PMID:
27876662
49.

Buzz Juice: Neurological sequelae of synthetic cannabinoids.

Kak M, Mikhail F, Yano ST, Guan R, Lukas RV.

J Clin Neurosci. 2017 Mar;37:43. doi: 10.1016/j.jocn.2016.10.046. Epub 2016 Nov 16.

PMID:
27865819
50.

Ambulatory training in neurology education.

Lukas RV, Blood AD, Brorson JR, Albert DVF.

J Neurol Sci. 2017 Jan 15;372:506-509. doi: 10.1016/j.jns.2016.11.008. Epub 2016 Nov 5.

PMID:
27838003

Supplemental Content

Loading ...
Support Center